Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
RESEARCH TOOLSreports
Holding HRMY?
Track your performance easily
HRMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$28.14 - $41.61
Previous Close$34.28
Volume2.98M
Average Volume (3M)785.33K
Market Cap
$1.93B
Enterprise Value$1.71B
Total Cash (Recent Filing)$410.48M
Total Debt (Recent Filing)$182.85M
Price to Earnings (P/E)16.2
Beta1.27
Next Earnings
Feb 19, 2025EPS Estimate
$0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.11
Shares Outstanding57,031,297
10 Day Avg. Volume567,559
30 Day Avg. Volume785,328
Standard Deviation0.13
R-Squared0.08
Alpha-0.00141
Financial Highlights & Ratios
Price to Book (P/B)3.28
Price to Sales (P/S)2.87
Price to Cash Flow (P/CF)6.90
P/FCF Ratio6.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.50
Enterprise Value/Gross Profit3.70
Enterprise Value/Ebitda10.17
Forecast
1Y Price Target
$51.43Price Target Upside50.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Harmony Biosciences Holdings News
PremiumCompany Announcements
Harmony Biosciences: Strong Q3 and Future Growth
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHRMY reported a top- and bottom-line beat with Wakix net revenue surpassing consensus estimates.
Growth PotentialWAKIX, Harmony's lead product, is FDA-approved for type 1 and type 2 narcolepsy and is on track to generate significant revenues, representing a strong growth potential.
Strategic ValidationLundbeck's acquisition of a company with a similar drug mechanism as HRMY's EPX-100 validates HRMY's move into the rare epilepsy market.
Bears Say
Orexin Program DetailsThe market may have been disappointed by the lack of details on the orexin program at the Investor Day, which led to a decline in HRMY shares.
Sales ImpactHRMY shared that it now also expects an additional negative impact on 1Q24 Wakix sales due to the ransomware attack at Change Healthcare.
Stock PerformanceThe announcement of a secondary offering by HRMY's founding investors has caused a setback in the stock's performance.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
HRMY FAQ
What was Harmony Biosciences Holdings’s price range in the past 12 months?
Harmony Biosciences Holdings lowest stock price was $28.14 and its highest was $41.61 in the past 12 months.
What is Harmony Biosciences Holdings’s market cap?
Currently, no data Available
When is Harmony Biosciences Holdings’s upcoming earnings report date?
Harmony Biosciences Holdings’s upcoming earnings report date is Feb 19, 2025 which is in 59 days.
How were Harmony Biosciences Holdings’s earnings last quarter?
Harmony Biosciences Holdings released its earnings results on Oct 29, 2024. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.665 by $0.125.
Is Harmony Biosciences Holdings overvalued?
According to Wall Street analysts Harmony Biosciences Holdings’s price is currently Undervalued.
Does Harmony Biosciences Holdings pay dividends?
Harmony Biosciences Holdings does not currently pay dividends.
What is Harmony Biosciences Holdings’s EPS estimate?
Harmony Biosciences Holdings’s EPS estimate is $0.68.
How many shares outstanding does Harmony Biosciences Holdings have?
Harmony Biosciences Holdings has 57,031,296 shares outstanding.
What happened to Harmony Biosciences Holdings’s price movement after its last earnings report?
Harmony Biosciences Holdings reported an EPS of $0.79 in its last earnings report, beating expectations of $0.665. Following the earnings report the stock price went up 16.056%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings?
Among the largest hedge funds holding Harmony Biosciences Holdings’s share is Royce & Associates LLC. It holds Harmony Biosciences Holdings’s shares valued at 3M.
---
Harmony Biosciences Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.43 (50.03% Upside)
$51.43 (50.03% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 20.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $278.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.99%
12-Months-Change
Fundamentals
Return on Equity
22.75%
Trailing 12-Months
Asset Growth
19.33%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.
---
HRMY Company Deck
---
HRMY Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with a strong financial performance, robust pipeline, and strategic plans for future growth. Despite increased operating expenses and some long timelines for clinical data, the company maintains a positive trajectory with significant market opportunities.Read More>---
HRMY Stock 12 Month Forecast
Average Price Target
$51.43
▲(50.03% Upside)
Technical Analysis
Best Analysts Covering HRMY
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+0.55%
reiterated a buy rating 17 days ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +0.55% per trade.
---